Trujillo CMC, Londoño GA, Velásquez FCJ, Restrepo MR

Language: Spanish
References: 19
Page: 66-68
PDF size: 1924.62 Kb.

ABSTRACT

A 56-year-old woman presenting rhumatoid arthritis is reported. She complains because a lichenoid reaction secondary to subcutaneous application of adalimumab for three years. The diagnosis was confirmed with a biopsy. The lesions resolved completely after adalimumab withdrawal. Although anti-TNF alpha monoclonal antibodies have been introduced to the management of some autoimmune diseases, skin rashes because of these has been increasing, including lichen planus like inflammatory reactions.

REFERENCES

1. Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ et al. Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor- antagonists. J Am Acad Dermatol 2009; 61: 104-11.

2. Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factoralpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.

3. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.

4. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138: 1258-9.

5. Bovenschen JH, Kop EN, Van De Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat 2006; 17: 381-3.

6. De Simone C, Caldarola G, D’Agostino M, Rotoli M, Capizzi R, Amerio P. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008; 22: 626-7.

7. Battistella M, Rivet J, Bachelez H, Liote F. Lichen planus associated with etanercept. Br J Dermatol 2008; 158: 188-90.

8. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti- TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388-90.

9. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNFalpha- blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: R666-76.

10. Moss AC, Treister NS, Marsee DK, Cheifetz AS. Clinical challenges and images in GI: oral lichenoid reaction in a patient with Crohn’s disease receiving infliximab. Gastroenterology 2007; 132: 488-9.

11. Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNFalpha blockers: 11 cases [French]. Ann Dermatol Venereol 2007; 134: 337-42.

12. Seneschal J, Lepreux S, Bouyssou-Gauthier ML, Heliot-Hosten I, Economu A, Dehais J, et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol 2007; 87: 77-80.

13. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 54-7.

14. Erdem MT, Gulec AI, Kiziltunc A, Yildirim A, Atasoy M. Increased serum levels of tumor necrosis factor alpha in lichen planus. Dermatology 2003; 207: 367-70.

15. Yarom N. Etanercept for the management of oral lichen planus. Am J Clin Dermatol 2007; 8: 121.

16. De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF- alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-31.

17. Fiorentino DF. The yin and yang of TNFalpha inhibition. Arch Dermatol 2007; 143: 233-6.

18. Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCVrelated chronic active hepatitis. J Eur Acad Dermatol Venereol 2003; 17: 193-5.

19. Vigna-Pérez M, Abud-Mendoza C, Portillo- Salazar H et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2006; 141: 372-80.